The approved dose was 2 mg/kg given as an intravenous (IV) infusion for 30 minutes every 3 weeks
sjad211 Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A et al (2023) Is there a risk for semaglutide misuse
Without human trial data, clinicians and patients are making decisions based on incomplete information, and the self-reported adverse effect profile anxiety, palpitations, insomnia, fatigue is not benign enough to ignore
Lin YS, Weibel J, Landolt HP, Santini F, Garbazza C, Kistler J, et al
Indianapolis, IN: Eli Lily and Company
Revealing the association between vitamin D metabolic pathway gene variants and lung cancer risk: a systematic review and meta-analysis